Centers for Disease Control and Prevention Seeks Further Public Comment on Revised Traveler-based Genomic Surveillance Program
The Centers for Disease Control and Prevention (CDC) has opened a crucial 30-day public comment period regarding its Traveler-based Genomic Surveillance (TGS) program, signaling an intensified federal focus on early detection of communicable diseases entering the United States via international air travel. Published in the Federal Register on June 12, 2026, this notice provides an opportunity for the public and affected agencies to offer feedback on a revised information collection request, highlighting the program's evolving role in national and global biosurveillance. The TGS initiative represents a significant federal effort to proactively identify and track pathogens at the nation's borders, adapting its methodology to address emerging public health threats.
The Evolving Landscape of Traveler Surveillance
The primary objective of the CDC's TGS program is to monitor for communicable diseases among arriving international air travelers at designated U.S. airports. This surveillance is designed to achieve two key goals: the early detection of imported communicable diseases that pose a public health concern and the critical filling of gaps in global biosurveillance efforts by tracking trends in the worldwide circulation of such pathogens. Initially focused primarily on SARS-CoV-2, the program has undergone significant revisions. The updated TGS framework broadens its scope to include testing for a wider array of pathogens beyond the coronavirus, reflecting a comprehensive approach to infectious disease monitoring. This expansion acknowledges the dynamic nature of global health threats and the necessity for adaptable surveillance mechanisms.
How the TGS Program Operates
Participation in the TGS program is entirely voluntary for international travelers. Individuals who choose to participate at the airport first provide written, informed consent. Following consent, they complete a short, anonymous questionnaire designed to gather essential travel information and general demographic data. The CDC has streamlined this questionnaire based on prior data, feedback from participants, and direct input from airport program staff, resulting in fewer questions and improved wording for better comprehension and response rates.
A core component of the program involves participants self-collecting two lower nasal swab samples. One of these swabs is then pooled with other traveler swabs, typically in batches of five to ten samples. These pooled samples undergo initial testing using reverse transcription polymerase chain reaction (RT-PCR) technology, a common method for detecting genetic material of pathogens, to screen for organisms of public health importance. The pathogens currently targeted include SARS-CoV-2, Influenza A virus, and respiratory syncytial virus (RSV). If any pooled sample yields a positive result, all corresponding secondary swab samples from that pool, which are stored individually, are then tested separately. This two-tiered testing approach aims to efficiently identify positive cases. Further, pathogen genomic sequencing may be performed on positive samples to ascertain the specific lineage of the pathogen, providing crucial data for tracking disease spread and evolution. It is important to note that the program explicitly states that no human genetic testing is performed. Some samples may also be sent to the CDC for additional specialized testing.
Navigating the Paperwork Reduction Act
This latest Federal Register notice specifically concerns a revision to an information collection request previously approved under OMB Control Number 0920-1406. The Paperwork Reduction Act of 1995 (PRA) mandates that federal agencies seek public comment on proposed information collections to ensure they are necessary, minimally burdensome, and have practical utility. The CDC had previously solicited public comments on this proposed data collection on January 13, 2026, receiving four responses. The current notice reopens the comment period for an additional 30 days, providing further opportunity for stakeholders to voice their perspectives.
The Office of Management and Budget (OMB) is particularly interested in comments addressing several key areas: evaluating the necessity and practical utility of the proposed collection, assessing the accuracy of the estimated burden on respondents, identifying ways to enhance the quality and clarity of the information collected, and exploring methods to minimize respondent burden, including through technological means like electronic submissions. The CDC estimates an annualized burden of 26,667 hours for the program, based on an estimated 400,000 international air travelers participating annually, with each participant spending approximately four minutes (4/60 of an hour) on the questionnaire. There is no monetary cost to respondents beyond their time.
Implications for Public Health and Policy
The CDC's continued investment in the TGS program underscores a proactive public health strategy aimed at bolstering national preparedness against infectious diseases. By establishing a robust system for genomic surveillance at points of entry, the government seeks to gain a critical advantage in identifying novel pathogens, tracking variants, and understanding global disease transmission dynamics. The voluntary nature of the program, coupled with its anonymous questionnaire and explicit assurance against human genetic testing, is designed to balance public health objectives with individual privacy concerns.
However, such programs inevitably raise discussions about the scope of government surveillance, the ethics of data collection, and the potential for mission creep. The PRA review process serves as an important mechanism for public accountability, allowing for a thorough vetting of these issues. The feedback received during these comment periods can significantly influence the final design and implementation of federal data collection initiatives, ensuring they are both effective and respectful of public concerns. The ongoing need for global biosurveillance, particularly in an era of rapid international travel, positions programs like TGS at the forefront of preventative public health measures.
